As this cohort of myeloma patients was uniformly treated [43] with bortezomib-based induction regimen, followed by ASCT, and then thalidomide maintenance, methylation of RNF130/miR-340 was a potential novel prognostic marker for myeloma and hence warrants a prospective study in larger cohorts of myeloma samples. This evidence concerns the gene RNF130 and plasma cell myeloma.